| Mapping the human genetic architecture of COVID-19 Writing group Writing group leaders Pathak Gita A. 6 Andrews Shea J. 7 Kanai ... Nature 600 (7889), 472-477, 2021 | 748 | 2021 |
| Chemoimmunotherapy with methotrexate, cytarabine, thiotepa, and rituximab (MATRix regimen) in patients with primary CNS lymphoma: results of the first randomisation of the … AJM Ferreri, K Cwynarski, E Pulczynski, M Ponzoni, M Deckert, LS Politi, ... The Lancet Haematology 3 (5), e217-e227, 2016 | 546 | 2016 |
| Autoantibodies neutralizing type I IFNs are present in~ 4% of uninfected individuals over 70 years old and account for~ 20% of COVID-19 deaths P Bastard, A Gervais, T Le Voyer, J Rosain, Q Philippot, J Manry, ... Science immunology 6 (62), eabl4340, 2021 | 473 | 2021 |
| Alemtuzumab (Campath-1H) and CHOP chemotherapy as first-line treatment of peripheral T-cell lymphoma: results of a GITIL (Gruppo Italiano Terapie Innovative nei Linfomi … A Gallamini, F Zaja, C Patti, A Billio, MR Specchia, A Tucci, A Levis, ... Blood, The Journal of the American Society of Hematology 110 (7), 2316-2323, 2007 | 394 | 2007 |
| X-linked recessive TLR7 deficiency in~ 1% of men under 60 years old with life-threatening COVID-19 T Asano, B Boisson, F Onodi, D Matuozzo, M Moncada-Velez, ... Science immunology 6 (62), eabl4348, 2021 | 350 | 2021 |
| Whole-brain radiotherapy or autologous stem-cell transplantation as consolidation strategies after high-dose methotrexate-based chemoimmunotherapy in patients with primary CNS … AJM Ferreri, K Cwynarski, E Pulczynski, CP Fox, E Schorb, P La Rosée, ... The Lancet Haematology 4 (11), e510-e523, 2017 | 319 | 2017 |
| R-CVP versus R-CHOP versus R-FM for the initial treatment of patients with advanced-stage follicular lymphoma: results of the FOLL05 trial conducted by the Fondazione Italiana … M Federico, S Luminari, A Dondi, A Tucci, U Vitolo, L Rigacci, ... Journal of Clinical Oncology 31 (12), 1506-1513, 2013 | 318 | 2013 |
| A comprehensive geriatric assessment is more effective than clinical judgment to identify elderly diffuse large cell lymphoma patients who benefit from aggressive therapy A Tucci, S Ferrari, C Bottelli, E Borlenghi, M Drera, G Rossi Cancer: Interdisciplinary International Journal of the American Cancer …, 2009 | 311 | 2009 |
| Prospective, multicenter randomized GITMO/IIL trial comparing intensive (R-HDS) versus conventional (CHOP-R) chemoimmunotherapy in high-risk follicular lymphoma at diagnosis … M Ladetto, F De Marco, F Benedetti, U Vitolo, C Patti, A Rambaldi, ... Blood 111 (8), 4004-4013, 2008 | 295 | 2008 |
| Splenic marginal zone lymphoma: a prognostic model for clinical use L Arcaini, M Lazzarino, N Colombo, S Burcheri, E Boveri, M Paulli, ... Blood 107 (12), 4643-4649, 2006 | 276 | 2006 |
| Genome-wide DNA profiling of marginal zone lymphomas identifies subtype-specific lesions with an impact on the clinical outcome A Rinaldi, M Mian, E Chigrinova, L Arcaini, G Bhagat, U Novak, ... Blood, The Journal of the American Society of Hematology 117 (5), 1595-1604, 2011 | 211 | 2011 |
| Four versus six cycles of CHOP chemotherapy in combination with six applications of rituximab in patients with aggressive B-cell lymphoma with favourable prognosis (FLYER): a … V Poeschel, G Held, M Ziepert, M Witzens-Harig, H Holte, L Thurner, ... The Lancet 394 (10216), 2271-2281, 2019 | 209 | 2019 |
| Time-resolved systems immunology reveals a late juncture linked to fatal COVID-19 C Liu, AJ Martins, WW Lau, N Rachmaninoff, J Chen, L Imberti, ... Cell 184 (7), 1836-1857. e22, 2021 | 191 | 2021 |
| Fludarabine plus mitoxantrone with and without rituximab versus CHOP with and without rituximab as front-line treatment for patients with follicular lymphoma PL Zinzani, A Pulsoni, A Perrotti, S Soverini, F Zaja, A De Renzo, S Storti, ... Journal of clinical oncology 22 (13), 2654-2661, 2004 | 191 | 2004 |
| Antiviral treatment in patients with indolent B-cell lymphomas associated with HCV infection: a study of the Fondazione Italiana Linfomi L Arcaini, D Vallisa, S Rattotti, VV Ferretti, AJM Ferreri, P Bernuzzi, ... Annals of Oncology 25 (7), 1404-1410, 2014 | 174 | 2014 |
| Final results of the IELSG-19 randomized trial of mucosa-associated lymphoid tissue lymphoma: improved event-free and progression-free survival with rituximab plus chlorambucil … E Zucca, A Conconi, G Martinelli, R Bouabdallah, A Tucci, U Vitolo, ... Journal of Clinical Oncology, 2017 | 173 | 2017 |
| Comprehensive geriatric assessment is an essential tool to support treatment decisions in elderly patients with diffuse large B-cell lymphoma: a prospective multicenter … A Tucci, M Martelli, L Rigacci, P Riccomagno, MG Cabras, F Salvi, ... Leukemia & lymphoma 56 (4), 921-926, 2015 | 162 | 2015 |
| Rituximab-dose-dense chemotherapy with or without high-dose chemotherapy plus autologous stem-cell transplantation in high-risk diffuse large B-cell lymphoma (DLCL04): final … A Chiappella, M Martelli, E Angelucci, E Brusamolino, A Evangelista, ... The Lancet Oncology 18 (8), 1076-1088, 2017 | 146 | 2017 |
| Long-term results of the FOLL05 trial comparing R-CVP versus R-CHOP versus R-FM for the initial treatment of patients with advanced-stage symptomatic follicular lymphoma S Luminari, A Ferrari, M Manni, A Dondi, A Chiarenza, F Merli, C Rusconi, ... Journal of Clinical Oncology 36 (7), 689-696, 2018 | 139 | 2018 |
| The risk of COVID-19 death is much greater and age dependent with type I IFN autoantibodies J Manry, P Bastard, A Gervais, T Le Voyer, J Rosain, Q Philippot, ... Proceedings of the National Academy of Sciences 119 (21), 2022 | 138 | 2022 |
